Reuters logo
10 个月前
BRIEF-Seattle Genetics, Agensys highlights promising Enfortumab Vedotin, ASG-15ME phase 1 data in metastatic urothelial cancer at 2016 ESMO congress
2016年10月7日 / 下午1点17分 / 10 个月前

BRIEF-Seattle Genetics, Agensys highlights promising Enfortumab Vedotin, ASG-15ME phase 1 data in metastatic urothelial cancer at 2016 ESMO congress

Oct 7 (Reuters) - Seattle Genetics Inc :

* Seattle Genetics and Agensys, an affiliate of Astellas, highlight promising enfortumab vedotin (ASG-22ME) and ASG-15ME phase 1 data in metastatic urothelial cancer at 2016 ESMO congress Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below